Divi's Laboratories Limited (DIVISLAB)
🎯 Key Takeaways
- Divi's Laboratories is in a strong growth phase, transitioning from a mature cash cow to a high-margin expansion stage. The company has demonstrated consistent revenue and profit growth over the past two years, with improving operational efficiency and capital allocation discipline.
- Revenue declined 4.1% QoQ to ₹2,604 in Q3FY26.
- ⚠️ The company is under tax scrutiny with a Draft Assessment Order proposing ₹570.51 crores in additions for FY22-23 related to transfer pricing and corp
📖 The Story
Divi's Laboratories is in a strong growth phase, transitioning from a mature cash cow to a high-margin expansion stage. The company has demonstrated consistent revenue and profit growth over the past two years, with improving operational efficiency and capital allocation discipline. Management is actively investing in capacity and talent while maintaining a conservative balance sheet and returning capital through dividends.
📰 What's Happening
In Q1 FY26, Divi's reported standalone revenue of ₹3,037 crores and consolidated revenue of ₹3,144 crores, up from ₹2,529 crores and ₹2,319 crores YoY respectively. Profit after tax rose to ₹891 crores standalone and ₹902 crores consolidated, up from ₹557 crores and ₹545 crores YoY. The Board approved senior management appointments effective August 1, 2026, signaling confidence in future execution. The company also declared a ₹30 per share dividend for FY25-26, payable post-AGM approval on August 10, 2026, subject to shareholder record date of July 24, 2026.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 |
| Operating Profit | 810 | 701 | 822 | 825 | 972 | 848 | 1,033 | 904 |
| OPM % | 31.7% | 29.4% | 30.6% | 32.0% | 34.3% | 30.3% | 32.7% | 34.2% |
| Net Profit | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 |
| EPS | ₹20.25 | ₹16.20 | ₹19.20 | ₹22.20 | ₹24.93 | ₹20.49 | ₹25.97 | ₹21.98 |
Revenue and profitability have shown a clear upward trend over the past eight quarters, with YoY growth accelerating in recent periods. The company's OPM has expanded from ~29% in Q1 FY25 to 34.2% in Q3 FY26, reflecting improved pricing power and cost discipline. Despite a slight dip in revenue from Q2 to Q3 FY26 (₹2,715 to ₹2,604 crores), profitability remained stable, indicating effective margin management. This trajectory aligns with management's focus on high-margin API and custom synthesis segments.
🔮 Management Outlook & What's Next
Management has not provided formal forward-looking guidance in the latest filings. However, the Board's approval of new senior appointments and continued investment in operations suggest confidence in sustained growth. The company remains focused on expanding its global footprint and regulatory approvals, particularly in the US and EU markets, as highlighted in prior investor presentations.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2023-2024 | 2023-2024 | 2024-2025 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 53 | 53 | 53 | 53 | 53 |
| Reserves | 12,624 | 13,518 | 13,664 | 14,916 | 15,360 |
| Borrowings | 2 | 0 | 5 | 2 | 89 |
| Total Liabilities | 1,606 | 1,899 | 1,869 | 1,963 | 2,738 |
| Fixed Assets | 4,648 | 4,733 | 4,652 | 5,437 | 5,672 |
| Investments | 80 | 82 | 85 | 65 | 67 |
| Total Assets | 14,283 | 15,470 | 15,586 | 16,932 | 18,151 |
The balance sheet reflects a strong capital structure with negligible debt (₹89 crores as of 2025-26) and growing equity and reserves. Total assets have risen from ₹15,586 crores in 2023-24 to ₹18,151 crores in 2025-26, driven by reinvestment of earnings. The company is funding growth internally, with no reliance on external capital, supporting long-term financial resilience and flexibility.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 | 2020-2021 |
|---|---|---|
| Operating | +1,158 | +1,947 |
| Investing | +580 | +75 |
| Financing | -34 | -35 |
| Net Cash Flow | — | — |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. The company is under tax scrutiny with a Draft Assessment Order proposing ₹570.51 crores in additions for FY22-23 related to transfer pricing and corporate tax adjustments, which could lead to additional liabilities and penalties if not resolved favorably. 2. Despite strong margins, revenue declined slightly in Q3 FY26 sequentially, raising questions about demand sustainability or execution in a competitive global API market. 3. Regulatory and geopolitical risks in key export markets (US, EU) could impact customer orders and pricing dynamics.
📋 Recent Filings
-
🟡 Board Meeting 1 August 2026Divi's Laboratories reported unaudited standalone financial results for Q1 FY2026 ending June 30, 2026, showing total income of **₹3,037 crores**, pro...
-
Announcement 1 August 2026Divi's Laboratories announced that the audio recording of its Q1 FY27 earnings conference call held on August 1, 2026, is now available on its investo...
-
Announcement 1 August 2026Divi's Laboratories announced its August 1, 2026 board meeting outcomes, approving unaudited standalone and consolidated financial results for Q1 FY20...
-
Announcement 31 July 2026Divi's Laboratories announced the retirement of two senior executives, Vice President of Procurement L. Ramesh Babu and Vice President of Projects D. ...
-
Announcement 24 July 2026Divi's Laboratories announced its Q1 FY27 earnings conference call on August 1, 2026, at 14:00 IST following the release of unaudited results for the ...
-
share transfer 7 July 2026Divi's Laboratories submitted a SEBI-mandated certificate from its share transfer agent KFin Technologies for the quarter ended June 30, 2026, confirm...
-
🟡 Board Meeting 11 June 2026Divi's Laboratories announced a ₹30 per share dividend for FY2025-26, payable after August 14, 2026, to shareholders on record as of July 24, 2026, su...
-
🔴 Financial Results 23 May 2026Divi's Laboratories announced that the audio recording of its Q4 FY26 earnings conference call held on May 23, 2026, is now available on its website u...
-
🔴 Financial Results 31 March 2026Divi's Laboratories announced closure of its trading window effective April 1, 2026, ahead of audited financial results for the quarter and year ended...
-
🔴 Announcement 21 March 2026Divi's Laboratories received a Draft Assessment Order from the Income Tax Authority for FY2022-23 proposing **₹570.51 crores** in additions/disallowan...
🧠 Analyst's Read
Divi's Laboratories is executing a disciplined growth strategy with strong profitability and financial health, but faces execution and regulatory risks. Investors should monitor resolution of the tax dispute and trends in order flow from key markets to assess near-term momentum.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when DIVISLAB files new disclosures
Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DIVISLAB — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research